The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study

doi:10.1002/cam4.5413

	The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study
	Yu, Xiaoqing 2,3; Si, Jinfei 4; Wei, Jingwen 5; Wang, Yanling 2,3; Sun, Yan 2,3; Jin, Jianan 2,3; Zhang, Xiaoyan 1; Ma, Tonghui 1; Song, Zhengbo 2,3
刊名	CANCER MEDICINE
	2022-11-15
关键词	EGFR-TKIs non-small cell lung cancer (NSCLC) real-world study survival outcome
ISSN号	2045-7634
DOI	10.1002/cam4.5413
通讯作者	Song, Zhengbo(songzb@zjcc.org.cn)
英文摘要	Background Few large-scale studies have been published using real-world data related to overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR)-mutant lung cancer patients; therefore, little is known regarding the characteristics of patients who could benefit most from EGFR-tyrosine kinase inhibitors (TKIs). Our study aimed to assess whether EGFR-TKI treatment confers survival benefits among advanced non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations in the Chinese population. Patients and Methods A total of 6451 advanced NSCLC patients were diagnosed between January 1, 2013 and June 30, 2019 in Zhejiang Cancer Hospital. Ultimately, 2864 patients with a confirmed EGFR mutation genotype were enrolled in our study. OS was measured from the time of diagnosis of advanced NSCLC until death or last follow-up. Results Median follow-up for OS of advanced EGFR-mutant NSCLC patients was 28.33 months in our study. Patients who received EGFR-TKIs demonstrated better survival compared to those without EGFR-TKI treatment (mOS: 29.77 vs. 22.97 months, p < 0.0001). A total of 451 patients switched to third-generation EGFR-TKI treatment and obtained a significantly better survival than those who adopted first-line third-generation EGFR-TKIs or those who did not receive third-generation EGFR-TKIs after disease progression with first- or second-generation EGFR-TKI treatment (mOS: 38.0 vs. 32.5 vs. 28.3 months, p < 0.0001). As for EGFR genotypes, patients with exon 19 deletion showed better OS, followed by those with L858R mutation (32.4 vs. 24.83 months, p = 0.0013). NGS versus PCR testing showed no statistical differences with respect to survival outcomes (mOS: 27.5 vs. 27.47 months, p = 0.6745). Conclusion Advanced EGFR-mutant patients treated with EGFR-TKIs obtained absolute superior survival in the Chinese population.
WOS关键词	TYROSINE KINASE INHIBITORS ; OPEN-LABEL ; PHASE-III ; 1ST-LINE TREATMENT ; ASIAN PATIENTS ; GEFITINIB ; ADENOCARCINOMA ; CHEMOTHERAPY ; MULTICENTER ; AFATINIB
WOS研究方向	Oncology
语种	英语
出版者	WILEY
WOS记录号	WOS:000884117300001
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/130411]
专题	中国科学院合肥物质科学研究院
通讯作者	Song, Zhengbo
作者单位	1.Genetron Hlth Beijing Technol Co Ltd, Dept Translat Med, Beijing, Peoples R China 2.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Clin Trial, Canc Hosp, Hangzhou, Peoples R China 4.Zhejiang Chinese Med Univ, Dept Oncol, Clin Med Coll 2, Hangzhou, Peoples R China 5.Wenzhou Med Univ, Dept Oncol, Clin Med Coll 1, Wenzhou, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Yu, Xiaoqing,Si, Jinfei,Wei, Jingwen,et al. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study[J]. CANCER MEDICINE,2022.
APA	Yu, Xiaoqing.,Si, Jinfei.,Wei, Jingwen.,Wang, Yanling.,Sun, Yan.,...&Song, Zhengbo.(2022).The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.CANCER MEDICINE.
MLA	Yu, Xiaoqing,et al."The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study".CANCER MEDICINE (2022).